The Week Ahead: Fed...
Health Care: Drugs
Arqule Inc. (ARQL: NASDAQ)
$5.68 0.15 | 2.71%
06/04/12 - 04:00 PM ET
Company Income Statement
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Sales | 47.31M | 29.22M | 25.20M | 14.14M |
| Cost of Sales | -1.74M | -2.56M | -2.61M | -1.17M |
| Gross Operating Profit | 49.05M | 31.78M | 27.81M | 15.31M |
| Selling, General, and Administrative Expenses | 13.37M | 13.48M | 13.32M | 16.92M |
| Research & Development | 45.01M | 47.03M | 49.50M | 49.63M |
| Operating Income before D & A (EBITDA) | -9.34M | -28.74M | -35.00M | -51.24M |
| Depreciation & Amortization | 1.74M | 2.56M | 2.61M | 1.17M |
| Interest Income | 317.00K | 619.00K | 1.09M | 3.34M |
| Other Income - Net | 20.00K | 266.00K | 1.59M | -1.33M |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -10.74M | -30.40M | -34.93M | -50.39M |
| Interest Expense | 25.00K | 274.00K | 655.00K | 472.00K |
| Pre-Tax Income | -10.76M | -30.68M | -35.59M | -50.86M |
| Income Taxes | 0.00 | -550.00K | 550.00K | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -10.76M | -30.13M | -36.14M | -50.86M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -10.76M | -30.13M | -36.14M | -50.86M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -10.76M | -30.13M | -36.14M | -50.86M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-10.76M | -30.13M | -36.14M | -50.86M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -10.76M | -30.13M | -36.14M | -50.86M |
| Basic EPS from Continuing Ops. | -0.20 | -0.68 | -0.82 | -1.16 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.20 | -0.68 | -0.82 | -1.16 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.20 | -0.68 | -0.82 | -1.16 |
| Basic Normalized Net Income/Share | -0.20 | -0.68 | -0.82 | -1.16 |
| EPS fr Continuing Ops. | -0.20 | -0.68 | -0.82 | -1.16 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.20 | -0.68 | -0.82 | -1.16 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.20 | -0.68 | -0.82 | -1.16 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.20 | -0.68 | -0.82 | -1.16 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with ARQL
- Portfolio NameUser Type
- Contributor22 Biopharma Stocks With Br...
- UserGFNN Stockdiagnostics 11
- ContributorStocks Under-$10 Moving Hig...
- Contributor7 Cancer Drug Stocks to Kno...
- UserASCO 2010
- UserDano Boy's List
- User2bullmates Portfolio 1
- UserASCO 2009 Part 2 the end of...
- UserBVF Inc.
- UserASCO is coming...Papers rel...
Latest ARQL Headlines from TheStreet
- ASCO 2012 Live Blog -- Saturday 06.02.12 | 07:06 am
- 22 Biopharma Stocks With Breakout Potential in 2012 05.22.12 | 08:05 am
- ASCO '12 Abstract Dump: Cancer Stocks in Focus (Update) 05.17.12 | 06:05 am
- ASCO '12 Abstract Dump: Cancer Stocks in Focus 05.16.12 | 06:05 pm
- 3 Stocks Under $10 Moving Higher 04.03.12 | 12:04 pm
- 7 Cancer Drug Stocks to Know Right Now 03.14.12 | 09:03 am
- Arqule Inc. Stock Downgraded (ARQL) 11.15.11 | 06:11 am
- Arqule Inc. Stock Upgraded (ARQL) 05.10.11 | 07:05 am
- Stocks Under $10: Soaring Biotech Stock
01.19.11 | 08:01 am - Crystallex International, Sprint Nextel: Early Volume Plays 06.07.10 | 08:06 am
Press Releases for ARQL
- Positive Phase 2 Study Results For Tivantinib In Previously Treated Hepatocellular Carcinoma To Be Presented At ASCO - Business Wire 06.02.12 | 07:06 am
- ArQule, Inc. To Present At Jefferies 2012 Global Healthcare Conferences - Business Wire 05.31.12 | 08:05 am
- ArQule And Daiichi Sankyo Announce Completion Of Patient Recruitment In Phase 3 Clinical Trial Of Tivantinib In Non-Small Cell Lung Cancer - Business Wire 05.18.12 | 07:05 am
- Positive Phase 2 Clinical Data With Tivantinib In Hepatocellular Carcinoma To Be Highlighted In Oral Presentation At 2012 Annual Meeting Of American Society Of Clinical Oncology - Business Wire 05.17.12 | 07:05 am
- ArQule Reports First Quarter 2012 Financial Results - Business Wire 05.03.12 | 07:05 am
- ArQule To Report First Quarter 2012 Financial Results On May 3, 2012 - Business Wire 04.26.12 | 08:04 am
- ArQule Announces Completion Of Common Stock Offering With Full Exercise Of Option To Purchase Additional Shares - Business Wire 04.16.12 | 04:04 pm
- ArQule Prices Public Offering Of Common Stock - Business Wire 04.11.12 | 07:04 am
- ArQule Announces Proposed Public Offering - Business Wire 04.10.12 | 07:04 am
- ArQule Announces Presentations At AACR 102nd Annual Meeting - Business Wire 03.29.12 | 08:03 am
Partner Headlines for ARQL
- Stock Insights: Dendreon, Medtronic, FedEx, ArQule, Rentrak June 4th - Wall St. Cheat Sheet 06.04.12 | 10:06 am
- ArQule Announces Positive Phase 2 Study Results for Tivantinib in Previously Treated Hepatocellular Carcinoma - Benzinga 06.02.12 | 06:06 pm
- Biotechnology Stocks To Watch Ahead Of ASCO 2012: Part 3 - Seeking Alpha 05.25.12 | 08:05 pm
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 05.01.12 | 09:05 am
- Zacks #1 Rank Additions for Monday - Tale of the Tape - Zacks 04.02.12 | 09:04 am
- Company News for January 18, 2012 - Corporate Summary - Zacks 01.18.12 | 10:01 am
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 11.15.11 | 09:11 am
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 10.04.11 | 09:10 am
- Drugs to Watch at ASCO 2011 - Seeking Alpha 06.02.11 | 08:06 am
- Future Biotech Superstars - Seeking Alpha 03.30.11 | 09:03 am
